Scholarlink

<p>Inflammation and oxidative/nitrosative stress (O&amp;NS) are serious complications in non-communicable diseases (NCDs), including endocrine and metabolic and neurodegenerative diseases. The beneficial probiotic microbes, such as <i>Lactobacillus</i>, <i>Bifidobacterium</i>, and <i>Streptococcus</i>, can decrease O&amp;NS and inflammation. We conducted this systematic review and meta-analysis of randomized controlled trials (RCTs) with aims to elucidate the effects of probiotics on O&amp;NS and inflammation in NCDs. A systematic search of PubMed, Scopus, and EMBASE resulted in the inclusion of studies if they met the eligibility criteria. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data (combined effect size) were analyzed using Meta-Essentials software. Fifteen studies/16 trials with a total of 807 participants (421 cases/386 controls) were reviewed. There was high and moderate certainty of evidence (GRADE) for the effectiveness of probiotic intervention (vs. placebo) in increasing (↑) glutathione (GSH) levels (SMD(SE) = 0.89 (0.51)/<i>p</i> &lt; 0.05, 95%CI − 0.23 to 2.1, <i>I</i><sup>2</sup> = 92.77%) and total antioxidant capacity (TAC) (SMD(SE) = 0. 75 (0.22)/<i>p</i> &lt; 0.01, 95%CI 0.28 to 1.23, <i>I</i><sup>2</sup> = 87.50%) as well as decreased (↓) malondialdehyde (MDA) (SMD(SE) = 1.03 (0.31)/<i>p</i> &lt; 0.01, 95%CI 0.37 to 1.7, <i>I</i><sup>2</sup> = 93.88%) and C-reactive protein (hsCRP) (SMD(SE) = 0.74 (0.36)/<i>p</i> &lt; 0.05, 95%CI − 0.07 to 1.55, <i>I</i><sup>2</sup> = 94.32%). There were no effects on nitric oxide, 8-hydroxy-2′-deoxyguanosine, interleukin-6, and tumor necrosis factor-α. Subgroup analysis to reduce heterogeneity indicated probiotic effectiveness on strain number (one/↑GSH), age bracket (41–60&#xa0;years/↓MDA or &gt; 61&#xa0;years/↓hsCRP), and NCD (nervous system/neurodegenerative diseases/↑GSH and ↓hsCRP or rheumatoid arthritis/polycystic ovary syndrome/↑TAC). An overall low risk of bias was observed. In conclusion, probiotics may have beneficial effects on markers of O&amp;NS and inflammation in patients with NCDs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of Probiotics on Markers of Oxidative/Nitrosative Stress and Damage Associated with Inflammation in Non-communicable Diseases: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials

  • 期刊论文

  • 发表日期：

    2025年8月15日

查看全文
  • Natanny Swerts Silva,
  • Cláudio Daniel Cerdeira,
  • Tiago Marques dos Reis,
  • Maria Rita Rodrigues

摘要

Inflammation and oxidative/nitrosative stress (O&NS) are serious complications in non-communicable diseases (NCDs), including endocrine and metabolic and neurodegenerative diseases. The beneficial probiotic microbes, such as Lactobacillus, Bifidobacterium, and Streptococcus, can decrease O&NS and inflammation. We conducted this systematic review and meta-analysis of randomized controlled trials (RCTs) with aims to elucidate the effects of probiotics on O&NS and inflammation in NCDs. A systematic search of PubMed, Scopus, and EMBASE resulted in the inclusion of studies if they met the eligibility criteria. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data (combined effect size) were analyzed using Meta-Essentials software. Fifteen studies/16 trials with a total of 807 participants (421 cases/386 controls) were reviewed. There was high and moderate certainty of evidence (GRADE) for the effectiveness of probiotic intervention (vs. placebo) in increasing (↑) glutathione (GSH) levels (SMD(SE) = 0.89 (0.51)/p < 0.05, 95%CI − 0.23 to 2.1, I2 = 92.77%) and total antioxidant capacity (TAC) (SMD(SE) = 0. 75 (0.22)/p < 0.01, 95%CI 0.28 to 1.23, I2 = 87.50%) as well as decreased (↓) malondialdehyde (MDA) (SMD(SE) = 1.03 (0.31)/p < 0.01, 95%CI 0.37 to 1.7, I2 = 93.88%) and C-reactive protein (hsCRP) (SMD(SE) = 0.74 (0.36)/p < 0.05, 95%CI − 0.07 to 1.55, I2 = 94.32%). There were no effects on nitric oxide, 8-hydroxy-2′-deoxyguanosine, interleukin-6, and tumor necrosis factor-α. Subgroup analysis to reduce heterogeneity indicated probiotic effectiveness on strain number (one/↑GSH), age bracket (41–60 years/↓MDA or > 61 years/↓hsCRP), and NCD (nervous system/neurodegenerative diseases/↑GSH and ↓hsCRP or rheumatoid arthritis/polycystic ovary syndrome/↑TAC). An overall low risk of bias was observed. In conclusion, probiotics may have beneficial effects on markers of O&NS and inflammation in patients with NCDs.